Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
15.47
-0.33 (-2.09%)
At close: Jun 23, 2025, 4:00 PM
15.60
+0.13 (0.84%)
After-hours: Jun 23, 2025, 5:12 PM EDT

Company Description

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases.

It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren’s disease; and batoclimab for graves' disease and thyroid eye disease.

The company has a license agreement with HanAll Biopharma Co., Ltd. for the rights of intellectual property relating to IMVT-1402 and batoclimab.

Immunovant, Inc. was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Immunovant, Inc.
Immunovant logo
Country United States
Founded 2018
Industry Biotechnology
Sector Healthcare
Employees 362
CEO Eric Venker

Contact Details

Address:
320 West 37th Street, 6th Floor
New York, New York 10018
United States
Phone 917 580 3099
Website immunovant.com

Stock Details

Ticker Symbol IMVT
Exchange NASDAQ
Fiscal Year April - March
Reporting Currency USD
CIK Code 0001764013
CUSIP Number 45258J102
ISIN Number US45258J1025
Employer ID 83-2771572
SIC Code 2836

Key Executives

Name Position
Dr. Eric Venker M.D., Pharm.D. Chief Executive Officer and Director
Dr. Frank M. Torti M.B.A., M.D. Executive Chairperson of the Board
Dr. Jay S. Stout Ph.D. Chief Technology Officer
Tiago M. Girao CPA Chief Financial Officer
Melanie Gloria B.S.N. Chief Operating Officer
Christopher A. Van Tuyl Esq., J.D. Chief Legal Officer and Corporate Secretary
Lauren Schrier M.B.A. Vice President of Marketing
Christine Blodgett Senior Vice President of Human Resources
Andy Deig Senior Vice President of Strategic Finance
Dr. Michael Geffner M.B.A., M.D., Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Jun 13, 2025 144 Filing
Jun 3, 2025 144 Filing
May 29, 2025 10-K Annual Report
May 29, 2025 8-K Current Report
May 21, 2025 144 Filing
May 19, 2025 144 Filing
Apr 30, 2025 S-8 Securities to be offered to employees in employee benefit plans
Apr 21, 2025 SCHEDULE 13D/A Filing
Apr 21, 2025 8-K Current Report
Mar 26, 2025 SCHEDULE 13G Filing